Sara A. Hurvitz

2 months ago | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences. Video content above is prompted by the following:Briefly discuss how you approach treatment for patients with HER2-ultralow metastatic breast cancer.

2 months ago | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations. Video content above is prompted by the following:Please discuss the recent findings from the DESTINY-Breast06 trial, highlighting key efficacy and safety findings and their implications for the treatment of HER2-low/ultralow metastatic breast cancer.

Jan 22, 2025 | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates. Video content above is prompted by the following:Provide a brief overview of the treatment landscape for HER2-low advanced breast cancer.

Nov 27, 2024 | onclive.com | Sara A. Hurvitz

Trastuzumab Deruxtecan in Patients With HER2+ Advanced/Metastatic Breast Cancer With or Without Brain Metastases: DESTINY-Breast12 Primary ResultsDr. Sara A. Hurvitz presents the primary results from the DESTINY-Breast12 trial, highlighting the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive advanced/metastatic breast cancer, including those with stable or active brain metastases​.

Aug 10, 2024 | cancernetwork.com | Erika Hamilton |Rinath Jeselsohn |Sara A. Hurvitz |Dejan Juric |Hyo S Han |Melinda L. Telli | +8 more

BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeras (PROTAC) estrogen receptor (ER) degrader. In a phase 1/2 study (NCT04072952), vepdegestrant monotherapy had a favorable safety profile and encouraging clinical activity with robust ER degradation. The phase 1b cohort of this study is evaluating vepdegestrant plus the CDK4/6inhibitor palbociclib.